Events

Our educational content is delivered in a variety of formats for different learning styles and techniques, to maintain a high level of engagement and ongoing dialogues between you and your peers.

Multi-organ impact: Harnessing the benefits of SGLT2 inhibitors

CKD is a growing public health problem, affecting more than 840 million people worldwide and projected to become the 5th highest cause of death by 2040.

Reshaping kidney care – Establishing the full potential of SGLT2 inhibitors as standard-of-care

Several novel therapies have been approved for the treatment of CKD in recent years and one class of agents, SGLT2 inhibitors, have been positioned

Continuing lifesaving therapy in the cardiorenal patient: Practical guidance for managing hyperkalaemia

Cardiorenal disease is associated with an increased risk of morbidity, hospitalisation and mortality, and RAAS inhibitors are standard-of-care for these

SGLT2 inhibitors and renal protection – interpreting the latest guidance for patients with hypertension in CKD

Identify CKD and comorbid hypertension phenotypes and understand the poor prognostic implications for these patients

Events

Multi-organ impact: Harnessing the benefits of SGLT2 inhibitors

Reshaping kidney care – Establishing the full potential of SGLT2 inhibitors as standard-of-care

Continuing lifesaving therapy in the cardiorenal patient: Practical guidance for managing hyperkalaemia

SGLT2 inhibitors and renal protection – interpreting the latest guidance for patients with hypertension in CKD

This site is intended for HCPs only and is a free resource that provides independent education.